Beta-lactam antibiotic

Jump to: navigation, search

WikiDoc Resources for Beta-lactam antibiotic

Articles

Most recent articles on Beta-lactam antibiotic

Most cited articles on Beta-lactam antibiotic

Review articles on Beta-lactam antibiotic

Articles on Beta-lactam antibiotic in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Beta-lactam antibiotic

Images of Beta-lactam antibiotic

Photos of Beta-lactam antibiotic

Podcasts & MP3s on Beta-lactam antibiotic

Videos on Beta-lactam antibiotic

Evidence Based Medicine

Cochrane Collaboration on Beta-lactam antibiotic

Bandolier on Beta-lactam antibiotic

TRIP on Beta-lactam antibiotic

Clinical Trials

Ongoing Trials on Beta-lactam antibiotic at Clinical Trials.gov

Trial results on Beta-lactam antibiotic

Clinical Trials on Beta-lactam antibiotic at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Beta-lactam antibiotic

NICE Guidance on Beta-lactam antibiotic

NHS PRODIGY Guidance

FDA on Beta-lactam antibiotic

CDC on Beta-lactam antibiotic

Books

Books on Beta-lactam antibiotic

News

Beta-lactam antibiotic in the news

Be alerted to news on Beta-lactam antibiotic

News trends on Beta-lactam antibiotic

Commentary

Blogs on Beta-lactam antibiotic

Definitions

Definitions of Beta-lactam antibiotic

Patient Resources / Community

Patient resources on Beta-lactam antibiotic

Discussion groups on Beta-lactam antibiotic

Patient Handouts on Beta-lactam antibiotic

Directions to Hospitals Treating Beta-lactam antibiotic

Risk calculators and risk factors for Beta-lactam antibiotic

Healthcare Provider Resources

Symptoms of Beta-lactam antibiotic

Causes & Risk Factors for Beta-lactam antibiotic

Diagnostic studies for Beta-lactam antibiotic

Treatment of Beta-lactam antibiotic

Continuing Medical Education (CME)

CME Programs on Beta-lactam antibiotic

International

Beta-lactam antibiotic en Espanol

Beta-lactam antibiotic en Francais

Business

Beta-lactam antibiotic in the Marketplace

Patents on Beta-lactam antibiotic

Experimental / Informatics

List of terms related to Beta-lactam antibiotic


β-lactam antibiotics are a broad class of antibiotics which include penicillin derivatives, cephalosporins, monobactams, carbapenems and β-lactamase inhibitors; basically any antibiotic agent which contains a β-lactam nucleus in its molecular structure. They are the most widely used group of antibiotics available.

Clinical use

β-lactam antibiotics are indicated for the prophylaxis and treatment of bacterial infections caused by susceptible organisms. While traditionally β-lactam antibiotics were mainly active only against Gram-positive bacteria, the development of broad-spectrum β-lactam antibiotics active against various Gram-negative organisms has increased their usefulness.

Mode of action

β-Lactam antibiotics are bactericidal, and act by inhibiting the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs).

β-lactam antibiotics are analogues of D-alanyl-D-alanine - the terminal amino acid residues on the precursor NAM/NAG-peptide subunits of the nascent peptidoglycan layer. The structural similarity between β-lactam antibiotics and D-alanyl-D-alanine facilitates their binding to the active site of penicillin binding proteins (PBPs). The β-lactam nucleus of the molecule irreversibly binds to (acylates) the Ser403 residue of the PBP active site. This irreversible inhibition of the PBPs prevents the final crosslinking (transpeptidation) of the nascent peptidoglycan layer, disrupting cell wall synthesis.

Under normal circumstances peptidoglycan precursors signal a reorganisation of the bacterial cell wall and consequently trigger the activation of autolytic cell wall hydrolyses. Inhibition of cross-linkage by β-lactams causes a build-up of peptidoglycan precurors which triggers the digestion of existing peptidoglycan by autolytic hydrolases without the production of new peptidoglycan. This as a result further enhances the bactericidal action of β-lactam antibiotics.

Modes of resistance

By definition, all β-lactam antibiotics have a β-lactam ring in their structure. The effectiveness of these antibiotics relies on their ability to reach the PBP intact and their ability to bind to the PBP. Hence, there are 2 main modes of bacterial resistance to β-lactams, as discussed below.

The first mode of β-lactam resistance is due to enzymatic hydrolysis of the β-lactam ring. If the bacteria produces the enzymes β-lactamase or penicillinase, these enzymes will break open the β-lactam ring of the antibiotic, rendering the antibiotic ineffective. The genes encoding these enzymes may be inherently present on the bacterial chromosome or may be acquired via plasmid transfer, and beta-lactamase gene expression may be induced by exposure to beta-lactams. The production of a β-lactamase by a bacterium does not necessarily rule out all treatment options with β-lactam antibiotics. In some instances, β-lactam antibiotics may be co-administered with a β-lactamase inhibitor.

However, in all cases where infection with β-lactamase-producing bacteria is suspected, the choice of a suitable β-lactam antibiotic should be carefully considered prior to treatment. In particular, choosing appropriate β-lactam antibiotic therapy is highly important against organisms with inducible β-lactamase expression. If β-lactamase production is inducible, then failure to use the most appropriate β-lactam antibiotic therapy at the onset of treatment will result in induction of β-lactamase production, thereby making further efforts with other β-lactam antibiotics more difficult.

The second mode of β-lactam resistance is due to possession of altered penicillin binding proteins. β-lactams cannot bind as effectively to these altered PBPs, and as a result, the β-lactams are less effective at disrupting cell wall synthesis. Notable examples of this mode of resistance include methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae. Altered PBPs do not necessarily rule out all treatment options with β-lactam antibiotics.

Common β-lactam antibiotics

Penicillins

Main article: penicillin

Narrow spectrum penicillins

Narrow spectrum penicillinase-resistant penicillins

Narrow spectrum β-lactamase-resistant penicillins

Moderate spectrum penicillins

Broad spectrum penicillins

Extended Spectrum Penicillins

Cephalosporins

Main article: cephalosporin

First generation cephalosporins

Moderate spectrum.

Second generation cephalosporins

Moderate spectrum with anti-Haemophilus activity.

Second generation cephamycins

Moderate spectrum with anti-anaerobic activity.

Third generation cephalosporins

Broad spectrum.

Broad spectrum with anti-Pseudomonas activity.

Fourth generation cephalosporins

Broad spectrum with enhanced activity against Gram positive bacteria and beta-lactamase stability.

Carbapenems

Main article: carbapenem

Broadest spectrum of beta-lactam antibiotics.

Monobactams

Unlike other beta-lactams, there is no fused ring attached to beta-lactam nucleus. Thus, there is less probability of cross-sensitivity reactions.

Beta-lactamase inhibitors

Negligible antimicrobial activity although they contain the beta-lactam ring. Their sole purpose is to prevent the inactivation of beta-lactam antibiotics by binding the beta-lactamases, and as such, they are co-administered with beta-lactam antibiotics.

Adverse effects

Adverse drug reactions

Common adverse drug reactions (ADRs) for the β-lactam antibiotics include: diarrhea, nausea, rash, urticaria, superinfection (including candidiasis). (Rossi, 2004)

Infrequent ADRs include: fever, vomiting, erythema, dermatitis, angioedema, pseudomembranous colitis. (Rossi, 2004)

Pain and inflammation at the injection site is also common for parenterally-administered β-lactam antibiotics.

Allergy/hypersensitivity

Allergic reactions to any β-lactam antibiotic may occur in up to 10% of patients receiving that agent. Anaphylaxis will occur in approximately 0.01% of patients. (Rossi, 2004) There is perhaps a 5-10% cross-sensitivity between penicillin-derivatives, cephalosporins and carbapenems; but this figure has been challenged by various investigators.

Nevertheless, the risk of cross-reactivity is sufficient to warrant the contraindication of all β-lactam antibiotics in patients with a history of severe allergic reactions (urticaria, anaphylaxis, interstitial nephritis) to any β-lactam antibiotic.

References

de:Β-Lactam-Antibiotika eu:Betalaktamiko ko:베타-락탐계열 항생제 it:Beta-lattamici



Linked-in.jpg